Company: MYSEW
Filing Date: 2025-02-10
Form Type: 424B5
Source: 0001213900-25-011767
Chunk: 0

Company: Myseum, Inc.
Filing Date: 2025-02-10
Form: 424B5
Chunk 0
---
Filed Pursuant to Rule 424(b)(5)
Registration No. 333-268058

PROSPECTUS SUPPLEMENT
(to Prospectus dated December 6, 2022)

<div align='center'>Up to $6,000,000

Common Stock</div>

We have entered into a Sales
Agreement, or the Sales Agreement, with The Benchmark Company, LLC, or Benchmark, dated February 10, 2025, relating to shares of our common
stock, par value $0.0001 per share, offered by this prospectus. In accordance with the terms of the Sales Agreement, we may offer and
sell shares of our common stock having an aggregate offering price of up to $6 million, subject to certain limitations, as described below,
from time to time through or to Benchmark, acting as sales agent or principal.

Our common stock trades on
The Nasdaq Capital Market under the symbol “DATS.” On February 6, 2025, the last reported sale price of our common stock on
The Nasdaq Capital Market was $3.09 per share.

Sales of our common stock,
if any, under this prospectus may be made in sales deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated
under the Securities Act of 1933, as amended, or (the “Securities Act”). Benchmark is not required to sell any specific number
or dollar amount of securities, but will act as sales agent or principal on a best efforts basis and use commercially reasonable efforts
to sell on our behalf all of the shares of common stock requested to be sold by us, consistent with its normal trading and sales practices,
on mutually agreed terms between us and Benchmark. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.

Benchmark will be entitled
to compensation at a fixed commission rate equal to 4.0% of the gross sales price per common share sold under the Sales Agreement; provided
however, that if sales of common stock sold through Benchmark pursuant to the Sales Agreement exceeds $1,000,000 then the commission paid
to Benchmark will be reduced to 3.0% of the aggregate gross proceeds we receive from each sale of our common stock sold through Benchmark
pursuant to the Sales Agreement. In connection with the sale of our common stock on our behalf, Benchmark will be deemed to be an “underwriter”
within the meaning of the Securities Act and the